SCHEMBL7515598

SCHEMBL7515598

COc1ccc(S(=O)(=O)C(c2ccc3ccccc3c2)C(C)C(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
HTT P42858 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MMP13 P45452 3/20 0.49
MMP1 P03956 2/20 0.49
MMP9 P14780 2/20 0.49
ADAM17 P78536 1/20 0.49
AKR1C3 P42330 7/20 0.49
AKR1C2 P52895 7/20 0.49
PTGS2 P35354 3/20 0.49
PTGS1 P23219 3/20 0.49
TSHR P16473 2/20 0.49
CDC42 P60953 1/20 0.49
RAC1 P63000 1/20 0.49
CYP1A2 P05177 1/20 0.49
SLC22A6 Q4U2R8 1/20 0.49
NPC1 O15118 2/20 0.46
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207784 0.87 MMP2 (0.54) SMN1; SMN2LMNATDP1MMP13MMP1
SCHEMBL6934674 0.86 MMP1 (0.48) SMN1; SMN2LMNATDP1HTTL3MBTL1
SCHEMBL9768697 0.75 AKR1C3 (0.54) LMNAAKR1C3AKR1C2PTGS2PTGS1
SCHEMBL7417705 0.75 MMP1 (0.48) SMN1; SMN2LMNATDP1HTTL3MBTL1
SCHEMBL7626661 0.74 MMP13 (0.47) HTTMMP13MMP1MMP9ADAM17
SCHEMBL7207035 0.74 MMP1 (0.54) HTTMMP13MMP1MMP9MMP2
Naproxen SCHEMBL23753934 0.73 AKR1C3 (0.88) LMNATDP1L3MBTL1AKR1C3AKR1C2
SCHEMBL15617672 0.73 NPC1 (0.58) SMN1; SMN2LMNATDP1HTTL3MBTL1
SCHEMBL6928764 0.73 MMP9 (0.77) SMN1; SMN2LMNATDP1HTTL3MBTL1
SCHEMBL6932013 0.72 ALDH1A1 (0.55) SMN1; SMN2LMNATDP1HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006922-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors AMERICAN CYANAMID COMPANY (US) 2002-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006922-A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors MMP12, ADAM33, MMP2 SMN1; SMN2 3424/4885LMNA 3266/4885TDP1 3272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.